Robert Davis, Merck CEO

July 28, 2022 10:40 AM EDT

What can Merck afford to buy now? ‘ANYTHING’ it wants

With Keytruda bulling its way past the $5 billion mark for Q2 sales, you could say that the top execs at Merck can be believed …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE LOG IN

ENDPOINTS CAREERS

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

view job offer post your job now

TRENDING NOW

Trump asks 'very tough hombre' Dr. Oz to lead MFN talks

US warns drugmakers against misrepresenting cost of imported products

About 5% of CBER and CDER left after FDA staff cuts, analysis finds

Meet the ‘first sale’ rule: A customs loophole pharma companies could use to ease tariff impact

Endpoints 100 biotech survey: Welcome to the summer of biotech’s discontent

sponsored

Does your supply chain hold up under pressure for high-risk temperature-critical shipments?